S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
US Dollar Replaced By "Biden Bucks"? (Ad)
NASDAQ:TALS

Talaris Therapeutics - TALS Stock Forecast, Price & News

$4.85
+0.16 (+3.41%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.63
$5.06
50-Day Range
$2.30
$8.75
52-Week Range
$2.04
$17.48
Volume
81,479 shs
Average Volume
157,123 shs
Market Capitalization
$201.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.25

Talaris Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
276.3% Upside
$18.25 Price Target
Short Interest
Healthy
3.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Talaris Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$383,766 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.80) to ($1.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

96th out of 1,135 stocks

Biological Products, Except Diagnostic Industry

14th out of 180 stocks

About Talaris Therapeutics

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Talaris Therapeutics Price Performance

Shares of TALS opened at $4.85 on Friday. The firm has a market cap of $201.08 million, a P/E ratio of -3.26 and a beta of 3.01. The stock has a 50 day simple moving average of $5.31 and a two-hundred day simple moving average of $7.21. Talaris Therapeutics has a 1 year low of $2.04 and a 1 year high of $17.48.

Talaris Therapeutics (NASDAQ:TALS - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). On average, equities analysts anticipate that Talaris Therapeutics will post -1.8 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TALS shares. SVB Leerink cut Talaris Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $21.00 to $7.00 in a research report on Thursday, June 30th. Guggenheim cut their price objective on Talaris Therapeutics to $23.00 and set a "na" rating for the company in a report on Monday, May 16th. Finally, Morgan Stanley lowered Talaris Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $20.00 to $8.00 in a report on Tuesday, July 5th.

Insiders Place Their Bets

In other news, Director Francois Nader bought 50,000 shares of the business's stock in a transaction on Tuesday, July 19th. The stock was acquired at an average price of $3.52 per share, with a total value of $176,000.00. Following the completion of the purchase, the director now directly owns 50,000 shares in the company, valued at $176,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Scott Requadt acquired 9,444 shares of the company's stock in a transaction dated Friday, July 22nd. The stock was purchased at an average price of $3.75 per share, with a total value of $35,415.00. Following the completion of the purchase, the chief executive officer now owns 460,680 shares in the company, valued at approximately $1,727,550. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Francois Nader acquired 50,000 shares of the company's stock in a transaction dated Tuesday, July 19th. The shares were bought at an average cost of $3.52 per share, with a total value of $176,000.00. Following the purchase, the director now owns 50,000 shares of the company's stock, valued at approximately $176,000. The disclosure for this purchase can be found here. Insiders bought a total of 104,562 shares of company stock valued at $383,766 over the last quarter. 16.60% of the stock is owned by corporate insiders.

Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TALS Stock News Headlines

What 4 Analyst Ratings Have To Say About Talaris Therapeutics
Talaris Therapeutics GAAP EPS of -$0.45
See More Headlines
Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TALS Company Calendar

Last Earnings
11/12/2021
Today
8/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TALS
Fax
N/A
Employees
112
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.25
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+276.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-47,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.93 per share

Miscellaneous

Free Float
34,581,000
Market Cap
$201.08 million
Optionable
Not Optionable
Beta
3.01

Key Executives

  • Mr. Scott Requadt J.D. (Age 54)
    L.L.B., M.B.A., MBA, Pres, CEO, Sec. & Director
    Comp: $748.06k
  • Dr. Suzanne T. Ildstad M.D. (Age 69)
    Founder, Chief Scientific Officer & Director
    Comp: $561.73k
  • Ms. Nancy Krieger M.D. (Age 55)
    Chief Medical Officer
    Comp: $591.31k
  • Ms. Mary Kay Fenton (Age 58)
    CFO & Treasurer
  • Mr. Michael Zdanowski (Age 55)
    Chief Technology Officer
  • Ms. Suzanne Tollerud
    VP of Corp. Devel.
  • Mr. Andrew Clyde Farnsworth (Age 63)
    Chief HR Officer
  • Mr. Eric Gornstein
    Head of New Product Planning
  • Ms. Farah Natoli
    Head of Portfolio & Program Management
  • Mr. Colby Suire Ph.D.
    Head of R&D













TALS Stock - Frequently Asked Questions

Should I buy or sell Talaris Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TALS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TALS, but not buy additional shares or sell existing shares.
View TALS analyst ratings
or view top-rated stocks.

What is Talaris Therapeutics' stock price forecast for 2022?

3 equities research analysts have issued 12-month price objectives for Talaris Therapeutics' shares. Their TALS share price forecasts range from $7.00 to $35.00. On average, they predict the company's share price to reach $18.25 in the next twelve months. This suggests a possible upside of 276.3% from the stock's current price.
View analysts price targets for TALS
or view top-rated stocks among Wall Street analysts.

How have TALS shares performed in 2022?

Talaris Therapeutics' stock was trading at $15.29 on January 1st, 2022. Since then, TALS shares have decreased by 68.3% and is now trading at $4.85.
View the best growth stocks for 2022 here
.

How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) issued its quarterly earnings results on Friday, November, 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.03.

When did Talaris Therapeutics IPO?

(TALS) raised $150 million in an IPO on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

What is Talaris Therapeutics' stock symbol?

Talaris Therapeutics trades on the NASDAQ under the ticker symbol "TALS."

Who are Talaris Therapeutics' major shareholders?

Talaris Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Ensign Peak Advisors Inc (0.10%), Rhumbline Advisers (0.08%), Bank of Montreal Can (0.05%), State Board of Administration of Florida Retirement System (0.03%), Virtu Financial LLC (0.03%) and Values First Advisors Inc. (0.03%). Insiders that own company stock include Francois Nader, Longitude Capital Partners Iii, Sandip Agarwala and Scott Requadt.
View institutional ownership trends
.

How do I buy shares of Talaris Therapeutics?

Shares of TALS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Talaris Therapeutics' stock price today?

One share of TALS stock can currently be purchased for approximately $4.85.

How much money does Talaris Therapeutics make?

Talaris Therapeutics (NASDAQ:TALS) has a market capitalization of $201.08 million. The company earns $-47,830,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does Talaris Therapeutics have?

The company employs 112 workers across the globe.

How can I contact Talaris Therapeutics?

The official website for the company is talaristx.com. The company can be reached via phone at 502-398-9250.

This page (NASDAQ:TALS) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.